LNCaP cells exposed to ceramic drug delivery treatment with epigallocatechin-3-gallate, thymoquinone, and tannic acid

Biomedical Sciences Instrumentation

Volumn 43, Issue , 2007, Pages 242-247

  Richards, La'Toya Ross ^a   Jones, Pamala ^a   Hughes, James ^a   Benghuzzi, Hamed ^a   Tucci, Michelle ^a  

^a UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

Author keywords

Antioxidants; Drug delivery; Epigallocatechin 3 gallate (EGCG); Prostate cancer; Tannic acid; Thymoquinone (TQ)

Indexed keywords

ALDEHYDES; CELL MEMBRANES; DRUG PRODUCTS; FREE RADICALS; NUTRITION; ONCOLOGY; ACIDS; CERAMIC MATERIALS; CYTOLOGY; DRUG DELIVERY; GROWTH KINETICS; INSTRUMENTS; LANDFORMS; REGRESSION ANALYSIS; TRANSMISSION CONTROL PROTOCOL;

CANCER DEVELOPMENT; EPIGALLOCATECHIN; FREE RADICAL DAMAGE; PROSTATE CANCER; TANNIC ACID; THYMOQUINONE (TQ);

DRUG DELIVERY; DISEASES;

ANTIOXIDANT; EPIGALLOCATECHIN GALLATE; MALONALDEHYDE; PROSTATE SPECIFIC ANTIGEN; TANNIN; THYMOQUINONE;

CELL COUNT; CELL DAMAGE; CELL FUNCTION; CELL GROWTH; CELL STRAIN LNCAP; CONFERENCE PAPER; DRUG DELIVERY SYSTEM; DRUG MECHANISM; HUMAN; HUMAN CELL; PROSTATE CANCER;

ANTICARCINOGENIC AGENTS; ANTIOXIDANTS; BENZOQUINONES; CATECHIN; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CERAMICS; DELAYED-ACTION PREPARATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; HUMANS; MALE; NEOPLASM PROTEINS; PROSTATIC NEOPLASMS; TANNINS;

ANTIOXIDANTS; EPIGALLOCATECHIN-3-GALLATE; PROSTATE CANCERS; TANNIC ACID; THYMOQUINONE;

EID: 34247643071     PISSN: 00678856     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (12)

1. Greene DR., Fitzpatrick, JM., Scardino, PT. Anatomy of the prostate and distribution of early prostate cancer. Seminar Surgeon Oncology 1995; 1:9-22.
2. Nagle RB. Intermediate filament expression in prostate cancer. Cancer Metastasis Review 1996: 473-482.
3. Ward (1999) Vitamin and mineral supplement use is associated with reduced risk of prostate cancer. Cancer Epidemiology Biomarkers and Prevention 8: 887-892.
4. Blute, ML., Iocca, A., and Zincke, H. Use of Gleason score, prostate specific antigen, seminal vesicle and margin status to predict biochemical failure after radical prostatectomy. Journal of Urology 2001; 165: 119-125.
5. Barry, MJ., Albertsen, PC., Cox, R., Jacobsen, SJ.Outcomes for men with clinically nonmetastatic prostate carcinoma managed with radical prostactectomy, external beam radiotherapy, or expectant management: a retrospective analysis. Cancer 2001; 12: 2302-2314
6. Krinsky, NI. Overview of lycopene, carotenoids, and disease prevention. Proc Soc Exp Biol Med. 1998; 2: 95-97.
7. Chan, J., Stampfer, M. J., Ma, J., Rimm, E., Willett, W., and Giovannucci, E. L. Supplemental vitamin E intake and prostate cancer risk in a large cohort of men in the United States. Cancer Epidemiology. Biomarkers. & Prevention. 2001; 8: 893-899.
8. DeWeese, T., Hruszkewyca, L., and Marnet, L. Oxidative stress in chemoprevention trials. Urology. 2001; 57: 137-140.
9. Yang, C.S., Maliakal, P., and Meng, X. (2002) Inhibition of carcinogenesis by tea. Annual Review of Pharmacology & Toxicology 42: 25-54
10. Yang, G-Yu., Liao, J., Kim, K., Yurkow, E.J., and Yang, C.S. (1998) Inhibition of growth and induction of apoptosis in human cancer cell lines by tea polyphenols. Carcinogenesis 19: 611-616.
11. Katiyar, S.K., and Mukhtar, H. (1996) Tea in chemoprevention of cancer: biological and experimental studies. International Journal of Oncology 8: 221-238.
12. Gopalakrishna, R. and Jaken, S. Protein kinase C signaling and oxidative stress. Free Radical Biological Medicin